Medicaid Expansion May Decrease Early Mortality in Some With NSCLC
Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.
A marketing authorization application seeking the approval of the combination of lazertinib and amivantamab in the first-line treatment of adult patients with advanced non–small cell lung cancer harboring EGFR mutations has been submitted to the European Medicines Agency.
Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.
Giving a glimpse into significant data and highlighting the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.
Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.